Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 72

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 72
---
 the impact of any resurgence                                              
 of COVID-19 or other pandemics on the performance of elective procedures; |

| ● | general economic, industry 
 and market conditions; and |

| ● | the other factors described 
 in this “Risk Factors.”     |

In recent years, the stock
market in general, and the market for medical device companies in particular, has experienced significant price and volume fluctuations
that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing
those price and volume fluctuations. Further, the stock market in general has been highly volatile due to recent geopolitical events
across the world. Broad market and industry factors may seriously affect the market price of our Ordinary Shares, regardless of our actual
operating performance. These fluctuations may be even more pronounced in the trading market for our shares shortly following this offering.
Following periods of such volatility in the market price of a company’s securities, securities class action litigation has often
been brought against that company. Because of the potential volatility of our share price, we may become the target of securities litigation
in the future. Securities litigation could result in substantial costs and divert management’s attention and resources from our
business.

Certain recent initial public offerings of companies with public floats comparable to the anticipated public float of Regentis have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may make it difficult for prospective investors to assess the value of our Ordinary Shares.

Our Ordinary Shares may be
subject to extreme volatility that is seemingly unrelated to the underlying performance of our business. Recently, companies with comparable
anticipated public floats and initial public offering sizes have experienced instances of extreme stock price run-ups followed by rapid
price declines, and such stock price volatility was seemingly unrelated to the respective company’s underlying performance. Although
the specific cause of such volatility is unclear, our anticipated public float may amplify the impact of the actions taken by a few shareholders
on the price of our Ordinary Shares, which may cause our share price to deviate, potentially significantly, from a price that better
reflects the underlying performance of our business. Should our Ordinary Shares experience run-ups and declines that are seemingly unrelated
to our actual or expected operating performance and financial condition or prospects, prospective investors may have difficulty assessing
the rapidly changing value of our Ordinary Shares. In addition, investors of shares of our Ordinary Shares may experience losses, which
may be material, if the price of our Ordinary Shares declines after this offering or